healio.com
Tremfya's FDA win as fully subcutaneous option for Crohn's may pave way to eclipse Stelara - Healio
A newly FDA-approved option (Tremfya/guselkumab) may offer more flexible dosing that could affect how people with moderate-to-severe Crohn’s start biologic treatment.
The approval includes head-to-head trial data versus an established therapy (Stelara), which may influence treatment choices and insurance coverage over time.
Adults with moderate-to-severe Crohn’s disease, patients currently on or considering biologic therapy, gastroenterologists, IBD clinical teams, and researchers tracking comparative biologic effectiveness.
What To Know
Tremfya (guselkumab) was approved by the FDA as the first IL-23 inhibitor offering both IV and fully subcutaneous induction options for moderately to severely active Crohn’s disease, based on phase 3 trials including head-to-head comparisons with Stelara (ustekinumab).
The article summarizes key trial program results (GRAVITI, GALAXI 2/3) and includes commentary on clinical implications and patient convenience from clinicians and a company spokesperson.
Tremfya is now an FDA-approved treatment option for moderate-to-severe Crohn’s disease and is notable for providing a fully subcutaneous induction regimen as well as IV induction.
The report highlights pooled phase 3 findings that the subcutaneous regimen showed higher rates of endoscopic and clinical endpoints versus placebo and that pooled analyses found statistical superiority versus ustekinumab on several endoscopic outcomes.
Practical points: The fully subcutaneous induction option may make starting and managing therapy easier for some patients and clinics compared with IV induction followed by subcutaneous maintenance.
The article draws on a Johnson & Johnson press release and includes expert perspective noting the potential for Tremfya to compete with or supplant existing therapies.
Limitations: This is a news summary of trial results and a company press release; it does not provide full study datasets, long-term safety beyond trial reports, or independent peer-reviewed analysis. Discuss treatment decisions with your gastroenterology team.
The article reports on FDA approval and company-reported phase 3 trial results (GRAVITI, GALAXI 2/3) including pooled analyses versus ustekinumab; it cites a Johnson & Johnson press release and expert commentary.
As a news piece, it summarizes results rather than presenting full trial data or independent peer-reviewed publications; no immediate treatment changes should be made without clinician consultation.
